

**ACI Formulations Limited**

**Third Quarter Report 2014**

**ACI Formulations Limited**  
**Statement of Financial Position**  
as at 30 September 2014  
Unaudited

Figures in '000'

	<u>Notes</u>	<u>30-Sep-14</u> <u>Taka</u>	<u>31-Dec-13</u> <u>Taka</u>
<b><u>Assets</u></b>			
<b>Non-current assets</b>			
Property, plant and equipment			
At cost/revaluation		1,404,402	1,363,150
Less: Accumulated depreciation		180,124	144,624
	5	1,224,278	1,218,526
Capital work-in-progress		11,548	26,283
Investment	6	14,308	2,808
<b>Total non-current assets</b>		<b>1,250,134</b>	<b>1,247,617</b>
<b>Current assets</b>			
Inventories	7	638,969	573,655
Trade receivables	8	512,936	454,261
Other receivables		7,817	7,129
Advances, deposits and prepayments	9	64,105	40,103
Advance income tax	10	99,649	94,366
Inter-company receivables	11	192,720	363,816
Cash and cash equivalents		39,598	118,780
<b>Total current assets</b>		<b>1,555,794</b>	<b>1,652,110</b>
<b>Total assets</b>		<b>2,805,928</b>	<b>2,899,727</b>
<b><u>Equity and liabilities</u></b>			
<b>Shareholders' equity</b>			
Share capital		450,000	450,000
Revaluation surplus		692,960	692,960
Retained earnings		585,667	587,512
<b>Total equity</b>		<b>1,728,627</b>	<b>1,730,472</b>
<b>Non-current liabilities</b>			
Long term liabilities	12	58,731	64,137
<b>Current liabilities</b>			
Bank overdraft		60,020	52,491
Short term bank loan		641,636	757,296
Trade payables		78,219	76,340
Other payables	13	131,033	99,535
Inter-company payables	14	-	3,336
Current tax liability		107,662	116,120
<b>Total current liabilities</b>		<b>1,018,570</b>	<b>1,105,118</b>
<b>Total equity and liabilities</b>		<b>2,805,928</b>	<b>2,899,727</b>



**Shusmita Anis**  
Managing Director



**Sheema Abed Rahman**  
Company Secretary


**ACI Formulations Limited**  
**Statement of Comprehensive Income**  
for the period of nine months ended on 30 September 2014  
Unaudited

Figures in '000'

	Notes	Jan to Sep 2014 Taka	Jan to Sep 2013 Taka	Jul to Sep 2014 Taka	Jul to Sep 2013 Taka
Revenue	15	2,038,724	1,665,286	685,260	529,295
Cost of sales	16	(1,525,720)	(1,256,853)	(504,204)	(407,481)
<b>Gross profit</b>		513,004	408,433	181,056	121,814
Administrative, selling and distribution expenses	17	(326,149)	(257,075)	(127,565)	(82,959)
<b>Results from operating activities</b>		186,855	151,358	53,491	38,855
Other income		4,784	4,837	1,043	2,001
Financing costs		(35,987)	(55,152)	(9,948)	(13,492)
		155,652	101,043	44,586	27,364
Provision for contribution to WPPF		(7,783)	(5,052)	(2,229)	(1,368)
<i>Profit before taxation</i>		147,869	95,991	42,357	25,996
Tax expenses		(37,214)	(24,003)	(11,028)	(6,360)
<b>Profit after tax</b>		110,655	71,988	31,329	19,636
Other comprehensive income		-	-	-	-
<b>Total comprehensive income</b>		<b>110,655</b>	<b>71,988</b>	<b>31,329</b>	<b>19,636</b>
<b>Earnings per share (EPS)</b>		<b>2.46</b>	<b>1.60</b>	<b>0.70</b>	<b>0.44</b>



**Shusmita Anis**  
Managing Director



**Sheema Abed Rahman**  
Company Secretary

**ACI Formulations Limited**

**Statement of Changes in Equity**

for the period of nine months ended on 30 September 2014


Unaudited

Figures in '000'

<u>Particulars</u>	<u>Paid-up capital Taka</u>	<u>Revaluation surplus Taka</u>	<u>Retained earnings Taka</u>	<u>Total Taka</u>
<b>Balance as at 31 December 2012</b>	<b>450,000</b>	<b>692,960</b>	<b>570,781</b>	<b>1,713,741</b>
<b>Comprehensive income for the period</b>				
Profit for the period	-	-	71,988	71,988
Total other comprehensive income net of tax	-	-	-	-
<b>Total Comprehensive income for the period</b>	<b>-</b>	<b>-</b>	<b>71,988</b>	<b>71,988</b>
<b>Contribution by and distributions to owners of the Company</b>				
Dividends to owners of the Company	-	-	(112,500)	(112,500)
<b>Total contributions by and distributions to owners of the Company</b>	<b>-</b>	<b>-</b>	<b>(112,500)</b>	<b>(112,500)</b>
<b>Balance as at 30 September 2013</b>	<b>450,000</b>	<b>692,960</b>	<b>530,269</b>	<b>1,673,229</b>
<b>Balance as at 31 December 2013</b>	<b>450,000</b>	<b>692,960</b>	<b>587,512</b>	<b>1,730,472</b>
<b>Comprehensive income for the period</b>				
Profit for the period	-	-	110,655	110,655
Total other comprehensive income net of tax	-	-	-	-
<b>Total Comprehensive income for the period</b>	<b>-</b>	<b>-</b>	<b>110,655</b>	<b>110,655</b>
<b>Contribution by and distributions to owners of the Company</b>				
Dividends to owners of the Company	-	-	(112,500)	(112,500)
<b>Total contributions by and distributions to owners of the Company</b>	<b>-</b>	<b>-</b>	<b>(112,500)</b>	<b>(112,500)</b>
<b>Balance at 30 September 2014</b>	<b>450,000</b>	<b>692,960</b>	<b>585,667</b>	<b>1,728,627</b>



**Shusmita Anis**  
Managing Director



**Sheema Abed Rahman**  
Company Secretary

**ACI Formulations Limited**  
**Statement of cash flows**

for the period of nine months ended on 30 September 2014


Unaudited

Figures in '000'

	Jan to Sep 2014 Taka	Jan to Sep 2013 Taka
<b>A) Cash flows from operating activities</b>		
Cash received from customers	2,005,012	1,839,428
Cash received from other income	4,784	4,837
	2,009,796	1,844,265
Cash received/(paid) from/(for):		
Purchase of inventories	(1,556,391)	(1,056,242)
Operating expenses	(269,461)	(241,067)
Other payables	(2,801)	439
Advances, deposits and prepayments	(24,002)	(6,499)
Payment for WPPF	(16,567)	-
Other receivables	(688)	-
	(1,869,910)	(1,303,369)
Cash generated from operating activities	139,886	540,896
Financing costs	(35,987)	(55,152)
Income tax	(57,618)	(30,945)
	(93,605)	(86,097)
<i>Net cash inflows/(outflows) from operating activities</i>	46,281	454,799
<b>B) Cash flows from investing activities</b>		
Acquisition of property, plant and equipment	(14,213)	(8,827)
Investment	(11,500)	(122)
Payments for capital work-in-progress	(12,304)	(15,902)
<i>Net cash used in investing activities</i>	(38,017)	(24,851)
<b>C) Cash flows from financing activities</b>		
Inter-company receivable/payable received/(paid)	127,464	(164,714)
Dividend paid	(106,780)	(111,688)
Short term bank loan received/(paid)	(115,660)	(190,615)
Long term bank loan received/(paid)	-	(2,313)
<i>Net cash from/(used in) financing activities</i>	(94,976)	(469,330)
<b>D) Net increase/(decrease) in cash and cash equivalents (A+B+C)</b>	(86,712)	(39,382)
<b>E) Cash and cash equivalents at 1 January</b>	66,290	6,797
<b>F) Cash and cash equivalents at 30 September (D+E)</b>	(20,422)	(32,585)
<b>Closing balance represents</b>		
Cash in hand and at bank	39,598	10,142
Bank overdraft	(60,020)	(42,727)
	(20,422)	(32,585)



**Shusmita Anis**  
Managing Director



**Sheema Abed Rahman**  
Company Secretary

**ACI Formulations Limited**  
**Consolidated Statement of Financial Position**  
as at 30 September 2014  
Unaudited

**Figures in '000'**

	<u>Notes</u>	<u>30-Sep-14</u> <u>Taka</u>
<b><u>Assets</u></b>		
<b>Non-current assets</b>		
Property, plant and equipment		
At cost/revaluation		1,409,040
Less: Accumulated depreciation		180,490
	5(a)	1,228,550
Biological asset		5,395
Capital work-in-progress		11,547
Investment	6(a)	2,808
Intangible asset		12,383
<b>Total non-current assets</b>		<u>1,260,683</u>
<b>Current assets</b>		
Inventories	7(a)	642,141
Trade receivables	8(a)	514,170
Other receivables		7,967
Advances, deposits and prepayments	9(a)	66,426
Advance income tax		99,649
Inter-company receivables		173,976
Cash and cash equivalents		41,026
<b>Total current assets</b>		<u>1,545,355</u>
<b>Total assets</b>		<u><u>2,806,038</u></u>
<b><u>Equity and liabilities</u></b>		
<b>Shareholders' equity</b>		
Share capital		450,000
Revaluation surplus		692,960
Retained earnings		585,120
		1,728,080
Minority Interest		(476)
<b>Total equity</b>		<u>1,727,604</u>
<b>Non-current liabilities</b>		
Long term liabilities	12(a)	58,836
<b>Current liabilities</b>		
Bank overdraft		60,020
Short term bank loan		641,636
Trade payables		78,345
Other payables		131,689
Obligation under finance lease- current portion		212
Current tax liability		107,696
<b>Total current liabilities</b>		<u>1,019,598</u>
<b>Total equity and liabilities</b>		<u><u>2,806,038</u></u>



**Shusmita Anis**  
Managing Director



**Sheema Abed Rahman**  
Company Secretary

**ACI Formulations Limited**  
**Consolidated Statement of Comprehensive Income**  
for the period of nine months ended on 30 September 2014  
**Unaudited**

		<u>Figures in '000'</u>	
		Jan to Sep 2014	Jan to Sep 2013
<u>Notes</u>		Taka	Taka
Revenue	15(a)	2,041,801	686,578
Cost of sales	16 (a)	(1,527,918)	(505,303)
<b>Gross profit</b>		513,883	181,275
Administrative, selling and distribution expenses	17(a)	(327,703)	(127,983)
<b>Results from operating activities</b>		186,180	53,292
Other income		4,784	1,043
Financing costs		(36,026)	(9,967)
		154,938	44,368
Provision for contribution to WPPF		(7,782)	(2,229)
<b>Profit before taxation</b>		147,156	42,139
Tax expenses		(37,230)	(10,656)
<b>Profit after tax</b>		109,926	31,483
Non-controlling interest		182	57
<b>Profit after tax &amp; minority interest</b>		110,108	31,540
<b>Earnings per share (EPS)</b>		2.45	0.70



**Shusmita Anis**  
Managing Director



**Sheema Abed Rahman**  
Company Secretary


**ACI Formulations Limited**  
**Consolidated Statement of Changes in Equity**  
for the period of nine months ended on 30 September 2014  
Unaudited

**Figures in '000'**

<u>Particulars</u>	<u>Paid up capital Taka</u>	<u>Revaluation surplus Taka</u>	<u>Retained earnings Taka</u>	<u>Total Taka</u>	<u>Non- controlling interest Taka</u>	<u>Total equity Taka</u>
Balance as at 31 December 2013	450,000	692,960	587,512	1,730,472	-	1,730,472
Non-controlling interest at acquisition date	-	-	-	-	(294)	(294)
<b>Comprehensive income for the period</b>						
Profit for the period	-	-	110,108	110,108	(182)	109,926
Total other comprehensive income net of tax	-	-	-	-	-	-
<b>Total Comprehensive income for the period</b>	<u>-</u>	<u>-</u>	<u>110,108</u>	<u>110,108</u>	<u>(182)</u>	<u>109,926</u>
<b>Contribution by and distributions to owners of the Company</b>						
Dividends to owners of the Company	-	-	(112,500)	(112,500)	-	(112,500)
<b>Total contributions by and distributions to owners of the Company</b>	<u>-</u>	<u>-</u>	<u>(112,500)</u>	<u>(112,500)</u>	<u>-</u>	<u>(112,500)</u>
<b>Balance at 30 September 2014</b>	<u>450,000</u>	<u>692,960</u>	<u>585,120</u>	<u>1,728,080</u>	<u>(476)</u>	<u>1,727,604</u>



**Shusmita Anis**  
Managing Director



**Sheema Abed Rahman**  
Company Secretary




**ACI Formulations Limited**  
**Consolidated Statement of Cash Flows**  
for the period of nine months ended on 30 September 2014  
Unaudited

**Figures in '000'**

	Jan to Sep 2014
	Taka
<b>A) Cash flows from operating activities</b>	
Cash received from customers	2,009,064
Cash received from other income	4,784
	2,013,848
Cash received/(paid) from/(for):	
Purchase of inventories	(1,559,025)
Operating expenses	(270,446)
Other payables	(2,802)
Advances, deposits and prepayments	(24,098)
Payment for WPPF	(16,567)
Other receivables	(688)
	(1,873,626)
Cash generated from operating activities	140,222
Financing costs	(36,026)
Income tax	(57,618)
	(93,644)
<i>Net cash inflows/(outflows) from operating activities</i>	46,578
<b>B) Cash flows from investing activities</b>	
Acquisition of property, plant and equipment	(14,255)
Investment	(11,353)
Payments for capital work-in-progress	(12,303)
<i>Net cash used in investing activities</i>	(37,911)
<b>C) Cash flows from financing activities</b>	
Inter-company receivable/payable received/(paid)	128,650
Dividend paid	(106,780)
Short term bank loan received/(paid)	(115,820)
Long term bank loan received/(paid)	-
<i>Net cash from/(used in) financing activities</i>	(93,950)
<b>D) Net increase/(decrease) in cash and cash equivalents (A+B+C)</b>	(85,283)
<b>E) Cash and cash equivalents at 1 January</b>	66,289
<b>F) Cash and cash equivalents at 30 September (D+E)</b>	(18,994)
<b>Closing balance represents</b>	
Cash in hand and at bank	41,026
Bank overdraft	(60,020)
	(18,994)



**Shusmita Anis**  
Managing Director



**Sheema Abed Rahman**  
Company Secretary

**ACI Formulations Limited**  
**Notes to the financial statements**  
**for the period of nine months ended on 30 September 2014**  
Unaudited

**1. Company profile:**

ACI Formulations Limited, a subsidiary of Advanced Chemical Industries Limited, domiciled in Bangladesh. The company's shares are listed with both Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited. The Principal activities of the company are manufacturing and marketing of a number of agrochemical, consumer brand and paint products.

**2. Subsidiaries of ACI Formulations Limited:**

ACI Formulations Limited has acquired 75% shares of Neem Laboratories (Pvt.) Ltd, Aloe Organics (Pvt.) Limited and Green Business & Marketing Company (BD) Limited. The effective date of acquisition was 28 February 2014. Neem Laboratories (Pvt.) Ltd is engaged in manufacturing and marketing of herbal products in small scale. On the other hand, the operations of Aloe Organics (Pvt.) Limited and Green Business & Marketing Company (BD) Limited are currently dormant. ACI Formulations Limited through its voting rights controls the operating and financing activities of above three entities.

**3. Consolidated Financial statements:**

In addition to the separate financial statements, the consolidated financial statements of the company have been prepared and included in this interim financial report as per BFRS 10: Consolidated Financial Statements. In separate Financial Statements, investment in subsidiaries has been carried at cost as per BAS 27: Separate Financial Statements.

**4. Selected explanatory notes:**

These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended 31 December 2013. This interim financial report includes only those selected explanatory notes as were deemed appropriate for better understanding of unaudited financial statements.

	<b>Figures in '000'</b>	
	30- Sep -14	31-Dec -13
	Taka	Taka
<b>5 Property, plant &amp; equipment at cost/ revaluation:</b>		
Opening balance	1,363,150	1,327,776
Addition during the period/year	41,252	35,374
	1,404,402	1,363,150
Accumulated depreciation at the end of period/year	(180,124)	(144,624)
	1,224,278	1,218,526
<b>5(a) Consolidated property, plant &amp; equipment at cost/ revaluation:</b>		
Opening balance	1,367,745	
Addition during the period/year	41,295	
	1,409,040	
Accumulated depreciation at the end of period/year	(180,490)	
	1,228,550	

	<u>30- Sep -14</u>	<u>31-Dec -13</u>
	<u>Taka</u>	<u>Taka</u>
<b>6. Investment</b>		
Investment in term deposit	2,733	2,733
Investment in Shares:		
ACI Motors Limited	75	75
Neem Laboratories (Pvt) Ltd.	3,834	-
Aloe Organic (Pvt) Ltd.	3,833	-
Green Business & Marketing Company (BD) Ltd.	3,833	-
	<u>14,308</u>	<u>2,808</u>
<b>6(a) Consolidated investment</b>		
Investment in term deposit	2,733	
Investment in Shares- ACI Motors Limited	75	
	<u>2,808</u>	
<b>7. Inventories</b>		
Raw materials	239,437	210,584
Packing materials	73,044	59,778
Finished goods	257,484	231,716
Work-in-process	-	2,421
Stock in transit	60,709	58,089
Other inventories	24,263	22,701
	<u>654,937</u>	<u>585,289</u>
Provision for slow moving Inventory	<u>(15,968)</u>	<u>(11,634)</u>
	<u>638,969</u>	<u>573,655</u>
<b>7(a) Consolidated inventories</b>		
Raw materials	240,579	
Packing materials	74,404	
Finished goods	258,087	
Work-in-process	67	
Stock in transit	60,709	
Other inventories	24,263	
	<u>658,109</u>	
Provision for slow moving Inventory	<u>(15,968)</u>	
	<u>642,141</u>	
<b>8. Trade receivables</b>		
Receivables due over six months	193,381	165,052
Receivables due below six months	416,267	370,871
	<u>609,648</u>	<u>535,923</u>
Provision for doubtful debts	<u>(96,712)</u>	<u>(81,662)</u>
	<u>512,936</u>	<u>454,261</u>
<b>8(a). Consolidated Trade receivables</b>		
Receivables due over six months	193,381	
Receivables due below six months	417,501	
	<u>610,882</u>	
Provision for doubtful debts	<u>(96,712)</u>	
	<u>514,170</u>	

<b>9. Advances, deposits &amp; prepayments</b>	<b>30- Sep -14</b>	<b>31-Dec -13</b>
	<u>Taka</u>	<u>Taka</u>
Advance to suppliers	27,435	23,366
Staff advances	2,925	5,305
Bank guarantee margin	13,832	1,064
VAT current account	7,160	1,556
Security money and tender deposits	11,673	5,972
Prepayments	1,080	2,840
	<u>64,105</u>	<u>40,103</u>
<b>9(a). Consolidated advances, deposits &amp; prepayments</b>		
Advance to suppliers	28,962	
Staff advances	2,925	
Bank guarantee margin	13,832	
VAT current account	7,160	
Security money and tender deposits	11,673	
Prepayments	1,874	
	<u>66,426</u>	
<b>10. Advance income tax</b>		
Balance as at 1st January	94,366	47,849
Paid during the period/year	57,618	46,517
	151,984	94,366
Adjustment during the period/year	(52,335)	-
	<u>99,649</u>	<u>94,366</u>
<b>11. Inter-company receivables</b>		
Advanced Chemical Industries Limited	173,976	363,816
Neem Laboratories (Pvt) Ltd.	18,744	-
	<u>192,720</u>	<u>363,816</u>
<b>12. Long term liabilities</b>		
Staff gratuity provision	8,434	7,178
Other long term liabilities	3,810	3,810
Deferred tax liabilities	46,487	53,149
	<u>58,731</u>	<u>64,137</u>
<b>12(a) Consolidated Long term liabilities</b>		
Staff gratuity provision	8,434	
Other long term liabilities	3,810	
Obligation under lease finance	105	
Deferred tax liabilities	46,487	
	<u>58,836</u>	
<b>13. Other payables</b>		
Creditor for expenses	97,804	67,229
Interest payable	7,629	3,639
Unpaid dividend	12,565	6,846
Security money payable	1,377	1,175
Withholding tax and VAT	924	1,127
Provision for workers' profit participation fund	10,734	19,519
	<u>131,033</u>	<u>99,535</u>

	<u>30-Sep-14</u> Taka	<u>31-Dec -13</u> Taka
<b>14. Inter-company payables</b>		
Premiaflex Plastics Limited	-	3,336
	<u>-</u>	<u>3,336</u>
	<u>Jan-Sep 14</u> Taka	<u>Jan- Sep 13</u> Taka
<b>15. Revenue</b>		
Crop Care & Public Health	1,080,280	817,581
Mosquito Coil	588,126	503,726
Aerosol	331,239	343,979
Paint	39,079	-
	<u>2,038,724</u>	<u>1,665,286</u>
<b>15(a). Consolidated revenue</b>		
Crop Care & Public Health	1,080,280	
Mosquito Coil	588,126	
Aerosol	331,239	
Paint & others	42,156	
	<u>2,041,801</u>	
<b>16. Cost of sales</b>		
Opening stock	504,500	601,970
Purchase	1,447,021	969,929
	<u>1,951,521</u>	<u>1,571,899</u>
Closing stock	(569,967)	(448,324)
	<u>1,381,554</u>	<u>1,123,575</u>
Manufacturing expenses	144,166	133,278
	<u>1,525,720</u>	<u>1,256,853</u>
<b>16(a). Consolidated cost of sales</b>		
Opening stock	507,043	
Purchase	1,447,419	
	<u>1,954,462</u>	
Closing stock	(571,236)	
	<u>1,383,226</u>	
Manufacturing expenses	144,692	
	<u>1,527,918</u>	
<b>17 Administrative, selling and distribution exp.</b>		
Administrative expenses	86,784	80,326
Distribution expenses	28,452	24,974
Selling expenses	210,913	151,775
	<u>326,149</u>	<u>257,075</u>
<b>17(a). Consolidated administrative, selling and distribution exp.</b>		
Administrative expenses	87,302	
Distribution expenses	28,970	
Selling expenses	211,431	
	<u>327,703</u>	

## 18. Segment reporting

The Company has three reportable segments, as described below, which are the Company's strategic divisions. The strategic divisions offer different products and services, and are managed separately because they require different technology and marketing strategies. For each of the strategic divisions, the Company's CEO reviews internal management reports at least on a quarterly basis. The following summary describes the operations in each of the Company's reportable segments:

**Crop Care and Public Health (CC & PH)** To manufacture and sell crop care and public health products.

**Mosquito Coil (M Coil)** To manufacture and sell mosquito coil products

**Aerosol** To manufacture and sell aerosol and air freshener products.


**Figures in '000'**

Particulars	CC & PH		M Coil		Aerosol		Unallocated		Total	
	Period ended on		Period ended on		Period ended on		Period ended on		Period ended on	
	30-Sep-14	30-Sep-13	30-Sep-14	30-Sep-13	30-Sep-14	30-Sep-13	30-Sep-14	30-Sep-13	30-Sep-14	30-Sep-13
	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka
Segment revenue:										
External revenues	1,080,280	817,581	-	-	-	-	42,156	-	1,122,436	817,581
Inter-segment revenues	-	-	588,126	503,726	331,239	343,979	-	-	919,365	847,705
<b>Total revenue</b>	<b>1,080,280</b>	<b>817,581</b>	<b>588,126</b>	<b>503,726</b>	<b>331,239</b>	<b>343,979</b>	<b>42,156</b>	<b>-</b>	<b>2,041,801</b>	<b>1,665,286</b>
Financing costs	(26,795)	(48,685)	(3,355)	(3,012)	(2,958)	(3,456)	(2,908)	-	(36,016)	(55,153)
Depreciation	(17,295)	(17,129)	(14,559)	(15,989)	(3,800)	(3,278)	(17)	-	(35,671)	(36,396)
Cost of sales excluding depreciation	(652,463)	(474,976)	(516,438)	(437,413)	(296,424)	(310,007)	(29,771)	-	(1,495,096)	(1,222,396)
Administrative, selling and distribution expenses excluding depreciation	(255,825)	(210,373)	(28,111)	(26,485)	(18,197)	(18,277)	(22,768)	-	(324,901)	(255,135)
Other income /(expense)	2,832	2,664	1	1	1,951	2,172	-	-	4,784	4,837
<b>Profit before tax</b>	<b>124,197</b>	<b>65,628</b>	<b>24,381</b>	<b>19,786</b>	<b>11,220</b>	<b>10,576</b>	<b>(12,643)</b>	<b>-</b>	<b>147,156</b>	<b>95,991</b>
<b>Reportable segment assets</b>	<b>1,663,028</b>	<b>1,504,802</b>	<b>738,297</b>	<b>807,787</b>	<b>253,933</b>	<b>227,790</b>	<b>150,779</b>	<b>56,784</b>	<b>2,806,037</b>	<b>2,597,163</b>
<b>Reportable segment liabilities</b>	<b>480,876</b>	<b>255,819</b>	<b>166,734</b>	<b>97,923</b>	<b>88,122</b>	<b>104,614</b>	<b>342,703</b>	<b>465,578</b>	<b>1,078,435</b>	<b>923,934</b>

19. Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.



**Shusmita Anis**  
Managing Director



**Sheema Abed Rahman**  
Company Secretary